Search

Learn about the journey of Cornelius Taabazuing, a rising young scientist who recently won the Tri-Institute Breakout Award for Young Investigators at the Sloan Kettering Institute.

… Tuesday, May 25, 2021 At this year’s Convocation, which is the highlight of Memorial Sloan Kettering’s academic efforts, Sloan Kettering Institute postdoctoral fellow Cornelius Taabazuing was honored with a prestigious award — the 2021 Tri-Institutional (Tri-I) Breakout Award for Junior Investigators

Four MSK researchers out of 15 winners nationwide were named recipients of the prestigious award. They will each receive a grant of up to $600,000 per year for seven years to support their research in cancer.

… Thursday, October 29, 2020 Four distinguished researchers at Memorial Sloan Kettering (MSK), Joan Massagué, PhD ; Maria Jasin, PhD ; David A. Scheinberg, MD, PhD ; and Hans-Guido Wendel, MD , were named recipients of the National Cancer Institute’s (NCI) 2020 Outstanding Investigator Award (OIA). As

Researchers have redesigned CAR T cells in hopes of improving immunotherapy treatment for multiple myeloma.

… Thursday, March 28, 2019 Summary CAR T cell therapy for multiple myeloma has targeted a protein called BCMA. However, many people treated with this immunotherapy have had their cancer return. Researchers have developed an additional class of CAR T cells that target a protein called GPRC5D. This might

Tomya Watt, Chief Diversity Officer and Vice President of Talent Acquisition and Mobility, was selected to receive the 2022 Moves Mentor Award from ’Moves‘ Magazine.

… Friday, May 20, 2022 Tomya Watt , Chief Diversity Officer and Vice President of Talent Acquisition and Mobility, was selected to receive the 2022 Moves Mentor Award from Moves  magazine. The award celebrates female leaders, the role they play in shaping the next generation, and the energy, expertise,

… Monday, March 3, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Vinod Balachandran Awarded the Marcus Foundation Medical Research Award Vinod Balachandran, MD Vinod Balachandran, MD  surgeon-scientist and Director of the Olayan Center for Cancer

Find out why people at risk of lung cancer are not getting screened and why they should.

… Friday, November 22, 2024 Summary Although a large study found that lung cancer screening was associated with a 20% reduction in lung cancer–related death, many of the people who would benefit most from screening are still not getting it. Lung cancer is by far the leading cause of cancer death in the

Descubra por qué las personas con riesgo de cáncer pulmonar no se están realizando la prueba de detección y por qué deberían hacerlo.

… Friday, November 22, 2024 Resumen Aunque un estudio amplio encontró que la detección del cáncer pulmonar se asoció con una reducción del 20 % en las muertes relacionadas con esta enfermedad, muchas de las personas que se beneficiarían más de esta prueba aún no la están realizando. El cáncer pulmonar

Research at Memorial Sloan Kettering will benefit from renewed support for The Starr Cancer Consortium and the Tri-Institutional Stem Cell Initiative totaling $105 million.

… Friday, June 1, 2012 Summary Research at Memorial Sloan Kettering will benefit from renewed support for The Starr Cancer Consortium and the Tri-Institutional Stem Cell Initiative totaling $105 million. The Starr Foundation announced on January 31 that it would provide renewed support totaling $55 million

Sacral neuromodulation has already helped patients with benignly caused fecal incontinence – can it do the same for rectal cancer patients following sphincter-preserving surgery?

… Thursday, May 19, 2016 Colorectal cancer is the second leading cause of cancer death in the United States. However, there are more than one million survivors of colon and rectal cancer nationwide, as improvements in screening, radiation, chemotherapy, and surgical techniques have contributed to a significant

Immune checkpoint inhibitors and adoptive T cell therapy have shown success in treating several cancers. Now both approaches are in trials for gynecologic cancers, and researchers think even more applications are possible.

… Friday, September 16, 2016 Recently, significant advances in our understanding of the tumor microenvironment and how tumors interact with the immune system have led to the development of two exciting therapeutic approaches for gynecologic cancers: immune checkpoint inhibitors and armored CAR T cells.